APO Research
Talk to an analyst

APO RESEARCH · REPORT

Platinum Anti-tumor Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Platinum Anti-tumor Drugs Market Analysis and Forecast 2026-2032

2 January 2026195 pages

Choose your research edition.

Industry ResearchPlatinum Anti-tumor Drugs Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Platinum Anti-tumor Drugs Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Platinum Anti-tumor Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Platinum Anti-tumor Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Platinum Anti-tumor Drugs Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Platinum Anti-tumor Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Platinum Anti-tumor Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Platinum Anti-tumor Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Platinum Anti-tumor Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Platinum Anti-tumor Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Platinum Anti-tumor Drugs include Teva, Sun Pharma, Sanofi, Novartis, Pfizer, Hengrui Medicine, Yi Bai Pharmaceutical, Viatris and SK Chemicals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Platinum Anti-tumor Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Platinum Anti-tumor Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Platinum Anti-tumor Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Platinum Anti-tumor Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Platinum Anti-tumor Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Platinum Anti-tumor Drugs revenue, projected growth trends, production technology, application and end-user industry.

Platinum Anti-tumor Drugs Segment by Company

Teva

Sun Pharma

Sanofi

Novartis

Pfizer

Hengrui Medicine

Yi Bai Pharmaceutical

Viatris

SK Chemicals

Qilu Pharmaceutical

Dr Reddy's Laboratories

Debiopharm

ASK Pharma

Accord Healthcare

Platinum Anti-tumor Drugs Segment by Type

Oxaliplatin

Carboplatin

Cisplatin

Other

Platinum Anti-tumor Drugs Segment by Application

Ovarian Cancer

Lung Cancer

Colorectal Cancer

Other

Platinum Anti-tumor Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Platinum Anti-tumor Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Platinum Anti-tumor Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Platinum Anti-tumor Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Platinum Anti-tumor Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Platinum Anti-tumor Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Platinum Anti-tumor Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Platinum Anti-tumor Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Oxaliplatin Major Player Table 3. Carboplatin Major Player Table 4. Cisplatin Major Player Table 5. Other Major Player Table 6. Global Platinum Anti-tumor Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Ovarian Cancer Major Player Table 8. Lung Cancer Major Player Table 9. Colorectal Cancer Major Player Table 10. Other Major Player Table 11. Platinum Anti-tumor Drugs Industry Trends Table 12. Platinum Anti-tumor Drugs Industry Drivers Table 13. Platinum Anti-tumor Drugs Industry Opportunities and Challenges Table 14. Platinum Anti-tumor Drugs Industry Restraints Table 15. Global Platinum Anti-tumor Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Platinum Anti-tumor Drugs Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Platinum Anti-tumor Drugs Market Share by Region (2021-2026) Table 18. Global Platinum Anti-tumor Drugs Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Platinum Anti-tumor Drugs Market Share by Region (2027-2032) Table 20. Global Platinum Anti-tumor Drugs Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Platinum Anti-tumor Drugs Revenue Market Share by Players (2021-2026) Table 22. Global Platinum Anti-tumor Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Platinum Anti-tumor Drugs Key Players Headquarters & Area Served Table 24. Global Platinum Anti-tumor Drugs Players, Product Type & Application Table 25. Global Platinum Anti-tumor Drugs Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Platinum Anti-tumor Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Platinum Anti-tumor Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Platinum Anti-tumor Drugs Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Platinum Anti-tumor Drugs Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Platinum Anti-tumor Drugs Revenue Market Share by Type (2021-2026) Table 32. Global Platinum Anti-tumor Drugs Revenue Market Share by Type (2027-2032) Table 33. Global Platinum Anti-tumor Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Platinum Anti-tumor Drugs Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Platinum Anti-tumor Drugs Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Platinum Anti-tumor Drugs Revenue Market Share by Application (2021-2026) Table 37. Global Platinum Anti-tumor Drugs Revenue Market Share by Application (2027-2032) Table 38. Teva Company Information Table 39. Teva Business Overview Table 40. Teva Platinum Anti-tumor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Teva Platinum Anti-tumor Drugs Product Portfolio Table 42. Teva Recent Development Table 43. Sun Pharma Company Information Table 44. Sun Pharma Business Overview Table 45. Sun Pharma Platinum Anti-tumor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Sun Pharma Platinum Anti-tumor Drugs Product Portfolio Table 47. Sun Pharma Recent Development Table 48. Sanofi Company Information Table 49. Sanofi Business Overview Table 50. Sanofi Platinum Anti-tumor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Sanofi Platinum Anti-tumor Drugs Product Portfolio Table 52. Sanofi Recent Development Table 53. Novartis Company Information Table 54. Novartis Business Overview Table 55. Novartis Platinum Anti-tumor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Novartis Platinum Anti-tumor Drugs Product Portfolio Table 57. Novartis Recent Development Table 58. Pfizer Company Information Table 59. Pfizer Business Overview Table 60. Pfizer Platinum Anti-tumor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Pfizer Platinum Anti-tumor Drugs Product Portfolio Table 62. Pfizer Recent Development Table 63. Hengrui Medicine Company Information Table 64. Hengrui Medicine Business Overview Table 65. Hengrui Medicine Platinum Anti-tumor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Hengrui Medicine Platinum Anti-tumor Drugs Product Portfolio Table 67. Hengrui Medicine Recent Development Table 68. Yi Bai Pharmaceutical Company Information Table 69. Yi Bai Pharmaceutical Business Overview Table 70. Yi Bai Pharmaceutical Platinum Anti-tumor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Yi Bai Pharmaceutical Platinum Anti-tumor Drugs Product Portfolio Table 72. Yi Bai Pharmaceutical Recent Development Table 73. Viatris Company Information Table 74. Viatris Business Overview Table 75. Viatris Platinum Anti-tumor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Viatris Platinum Anti-tumor Drugs Product Portfolio Table 77. Viatris Recent Development Table 78. SK Chemicals Company Information Table 79. SK Chemicals Business Overview Table 80. SK Chemicals Platinum Anti-tumor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. SK Chemicals Platinum Anti-tumor Drugs Product Portfolio Table 82. SK Chemicals Recent Development Table 83. Qilu Pharmaceutical Company Information Table 84. Qilu Pharmaceutical Business Overview Table 85. Qilu Pharmaceutical Platinum Anti-tumor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Qilu Pharmaceutical Platinum Anti-tumor Drugs Product Portfolio Table 87. Qilu Pharmaceutical Recent Development Table 88. Dr Reddy's Laboratories Company Information Table 89. Dr Reddy's Laboratories Business Overview Table 90. Dr Reddy's Laboratories Platinum Anti-tumor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Dr Reddy's Laboratories Platinum Anti-tumor Drugs Product Portfolio Table 92. Dr Reddy's Laboratories Recent Development Table 93. Debiopharm Company Information Table 94. Debiopharm Business Overview Table 95. Debiopharm Platinum Anti-tumor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Debiopharm Platinum Anti-tumor Drugs Product Portfolio Table 97. Debiopharm Recent Development Table 98. ASK Pharma Company Information Table 99. ASK Pharma Business Overview Table 100. ASK Pharma Platinum Anti-tumor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. ASK Pharma Platinum Anti-tumor Drugs Product Portfolio Table 102. ASK Pharma Recent Development Table 103. Accord Healthcare Company Information Table 104. Accord Healthcare Business Overview Table 105. Accord Healthcare Platinum Anti-tumor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Accord Healthcare Platinum Anti-tumor Drugs Product Portfolio Table 107. Accord Healthcare Recent Development Table 108. North America Platinum Anti-tumor Drugs Revenue by Type (2021-2026) & (US$ Million) Table 109. North America Platinum Anti-tumor Drugs Revenue by Type (2027-2032) & (US$ Million) Table 110. North America Platinum Anti-tumor Drugs Revenue by Application (2021-2026) & (US$ Million) Table 111. North America Platinum Anti-tumor Drugs Revenue by Application (2027-2032) & (US$ Million) Table 112. North America Platinum Anti-tumor Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 113. North America Platinum Anti-tumor Drugs Revenue by Country (2021-2026) & (US$ Million) Table 114. North America Platinum Anti-tumor Drugs Revenue by Country (US$ Million) & (2027-2032) Table 115. Europe Platinum Anti-tumor Drugs Revenue by Type (2021-2026) & (US$ Million) Table 116. Europe Platinum Anti-tumor Drugs Revenue by Type (2027-2032) & (US$ Million) Table 117. Europe Platinum Anti-tumor Drugs Revenue by Application (2021-2026) & (US$ Million) Table 118. Europe Platinum Anti-tumor Drugs Revenue by Application (2027-2032) & (US$ Million) Table 119. Europe Platinum Anti-tumor Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. Europe Platinum Anti-tumor Drugs Revenue by Country (2021-2026) & (US$ Million) Table 121. Europe Platinum Anti-tumor Drugs Revenue by Country (US$ Million) & (2027-2032) Table 122. China Platinum Anti-tumor Drugs Revenue by Type (2021-2026) & (US$ Million) Table 123. China Platinum Anti-tumor Drugs Revenue by Type (2027-2032) & (US$ Million) Table 124. China Platinum Anti-tumor Drugs Revenue by Application (2021-2026) & (US$ Million) Table 125. China Platinum Anti-tumor Drugs Revenue by Application (2027-2032) & (US$ Million) Table 126. Asia Platinum Anti-tumor Drugs Revenue by Type (2021-2026) & (US$ Million) Table 127. Asia Platinum Anti-tumor Drugs Revenue by Type (2027-2032) & (US$ Million) Table 128. Asia Platinum Anti-tumor Drugs Revenue by Application (2021-2026) & (US$ Million) Table 129. Asia Platinum Anti-tumor Drugs Revenue by Application (2027-2032) & (US$ Million) Table 130. Asia Platinum Anti-tumor Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 131. Asia Platinum Anti-tumor Drugs Revenue by Region (US$ Million) & (2021-2026) Table 132. Asia Platinum Anti-tumor Drugs Revenue by Region (US$ Million) & (2027-2032) Table 133. SAMEA Platinum Anti-tumor Drugs Revenue by Type (2021-2026) & (US$ Million) Table 134. SAMEA Platinum Anti-tumor Drugs Revenue by Type (2027-2032) & (US$ Million) Table 135. SAMEA Platinum Anti-tumor Drugs Revenue by Application (2021-2026) & (US$ Million) Table 136. SAMEA Platinum Anti-tumor Drugs Revenue by Application (2027-2032) & (US$ Million) Table 137. SAMEA Platinum Anti-tumor Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 138. SAMEA Platinum Anti-tumor Drugs Revenue by Country (2021-2026) & (US$ Million) Table 139. SAMEA Platinum Anti-tumor Drugs Revenue by Country (US$ Million) & (2027-2032) Table 140. Research Programs/Design for This Report Table 141. Authors List of This Report Table 142. Secondary Sources Table 143. Primary Sources List of Figures Figure 1. Platinum Anti-tumor Drugs Image Figure 2. Global Platinum Anti-tumor Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Platinum Anti-tumor Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Oxaliplatin Image Figure 5. Carboplatin Image Figure 6. Cisplatin Image Figure 7. Other Image Figure 8. Global Platinum Anti-tumor Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Platinum Anti-tumor Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 10. Ovarian Cancer Image Figure 11. Lung Cancer Image Figure 12. Colorectal Cancer Image Figure 13. Other Image Figure 14. Global Platinum Anti-tumor Drugs Market Size (US$ Million) & (2021-2032) Figure 15. Global Platinum Anti-tumor Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Platinum Anti-tumor Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Platinum Anti-tumor Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Platinum Anti-tumor Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Platinum Anti-tumor Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Platinum Anti-tumor Drugs Revenue Market Share by Type (2021-2032) Figure 22. Global Platinum Anti-tumor Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Platinum Anti-tumor Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Platinum Anti-tumor Drugs Revenue Market Share by Application (2021-2032) Figure 25. North America Platinum Anti-tumor Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Platinum Anti-tumor Drugs Revenue Share by Type (2021-2032) Figure 27. North America Platinum Anti-tumor Drugs Revenue Share by Application (2021-2032) Figure 28. North America Platinum Anti-tumor Drugs Revenue Share by Country (2021-2032) Figure 29. United States Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Platinum Anti-tumor Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Platinum Anti-tumor Drugs Revenue Share by Type (2021-2032) Figure 34. Europe Platinum Anti-tumor Drugs Revenue Share by Application (2021-2032) Figure 35. Europe Platinum Anti-tumor Drugs Revenue Share by Country (2021-2032) Figure 36. Germany Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Platinum Anti-tumor Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Platinum Anti-tumor Drugs Revenue Share by Type (2021-2032) Figure 46. China Platinum Anti-tumor Drugs Revenue Share by Application (2021-2032) Figure 47. Asia Platinum Anti-tumor Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Platinum Anti-tumor Drugs Revenue Share by Type (2021-2032) Figure 49. Asia Platinum Anti-tumor Drugs Revenue Share by Application (2021-2032) Figure 50. Asia Platinum Anti-tumor Drugs Revenue Share by Region (2021-2032) Figure 51. Japan Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Platinum Anti-tumor Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Platinum Anti-tumor Drugs Revenue Share by Type (2021-2032) Figure 59. SAMEA Platinum Anti-tumor Drugs Revenue Share by Application (2021-2032) Figure 60. SAMEA Platinum Anti-tumor Drugs Revenue Share by Country (2021-2032) Figure 61. Brazil Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Platinum Anti-tumor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Oxaliplatin
  • Carboplatin
  • Cisplatin
  • Other
Applications
  • Ovarian Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Other
Companies covered
  • Teva
  • Sun Pharma
  • Sanofi
  • Novartis
  • Pfizer
  • Hengrui Medicine
  • Yi Bai Pharmaceutical
  • Viatris
  • SK Chemicals
  • Qilu Pharmaceutical
  • Dr Reddy's Laboratories
  • Debiopharm
  • ASK Pharma
  • Accord Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Platinum Anti-tumor Drugs Market by Type
  3. 1.2.1 Global Platinum Anti-tumor Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Oxaliplatin
  5. 1.2.3 Carboplatin
  6. 1.2.4 Cisplatin
  7. 1.2.5 Other
  8. 1.3 Platinum Anti-tumor Drugs Market by Application
  9. 1.3.1 Global Platinum Anti-tumor Drugs Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Ovarian Cancer
  11. 1.3.3 Lung Cancer
  12. 1.3.4 Colorectal Cancer
  13. 1.3.5 Other
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Platinum Anti-tumor Drugs Market Dynamics
  1. 2.1 Platinum Anti-tumor Drugs Industry Trends
  2. 2.2 Platinum Anti-tumor Drugs Industry Drivers
  3. 2.3 Platinum Anti-tumor Drugs Industry Opportunities and Challenges
  4. 2.4 Platinum Anti-tumor Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Platinum Anti-tumor Drugs Market Perspective (2021-2032)
  2. 3.2 Global Platinum Anti-tumor Drugs Growth Trends by Region
  3. 3.2.1 Global Platinum Anti-tumor Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Platinum Anti-tumor Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Platinum Anti-tumor Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Platinum Anti-tumor Drugs Revenue by Players
  2. 4.1.1 Global Platinum Anti-tumor Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Platinum Anti-tumor Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Platinum Anti-tumor Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Platinum Anti-tumor Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Platinum Anti-tumor Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Platinum Anti-tumor Drugs Players, Product Type & Application
  8. 4.5 Global Platinum Anti-tumor Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Platinum Anti-tumor Drugs Market CR5 and HHI
  11. 4.6.3 2025 Platinum Anti-tumor Drugs Tier 1, Tier 2, and Tier 3
5 Platinum Anti-tumor Drugs Market Size by Type
  1. 5.1 Global Platinum Anti-tumor Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Platinum Anti-tumor Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Platinum Anti-tumor Drugs Revenue Market Share by Type (2021-2032)
6 Platinum Anti-tumor Drugs Market Size by Application
  1. 6.1 Global Platinum Anti-tumor Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Platinum Anti-tumor Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Platinum Anti-tumor Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Teva
  2. 7.1.1 Teva Company Information
  3. 7.1.2 Teva Business Overview
  4. 7.1.3 Teva Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Teva Platinum Anti-tumor Drugs Product Portfolio
  6. 7.1.5 Teva Recent Developments
  7. 7.2 Sun Pharma
  8. 7.2.1 Sun Pharma Company Information
  9. 7.2.2 Sun Pharma Business Overview
  10. 7.2.3 Sun Pharma Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Sun Pharma Platinum Anti-tumor Drugs Product Portfolio
  12. 7.2.5 Sun Pharma Recent Developments
  13. 7.3 Sanofi
  14. 7.3.1 Sanofi Company Information
  15. 7.3.2 Sanofi Business Overview
  16. 7.3.3 Sanofi Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sanofi Platinum Anti-tumor Drugs Product Portfolio
  18. 7.3.5 Sanofi Recent Developments
  19. 7.4 Novartis
  20. 7.4.1 Novartis Company Information
  21. 7.4.2 Novartis Business Overview
  22. 7.4.3 Novartis Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Novartis Platinum Anti-tumor Drugs Product Portfolio
  24. 7.4.5 Novartis Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Platinum Anti-tumor Drugs Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 Hengrui Medicine
  32. 7.6.1 Hengrui Medicine Company Information
  33. 7.6.2 Hengrui Medicine Business Overview
  34. 7.6.3 Hengrui Medicine Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Hengrui Medicine Platinum Anti-tumor Drugs Product Portfolio
  36. 7.6.5 Hengrui Medicine Recent Developments
  37. 7.7 Yi Bai Pharmaceutical
  38. 7.7.1 Yi Bai Pharmaceutical Company Information
  39. 7.7.2 Yi Bai Pharmaceutical Business Overview
  40. 7.7.3 Yi Bai Pharmaceutical Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Yi Bai Pharmaceutical Platinum Anti-tumor Drugs Product Portfolio
  42. 7.7.5 Yi Bai Pharmaceutical Recent Developments
  43. 7.8 Viatris
  44. 7.8.1 Viatris Company Information
  45. 7.8.2 Viatris Business Overview
  46. 7.8.3 Viatris Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Viatris Platinum Anti-tumor Drugs Product Portfolio
  48. 7.8.5 Viatris Recent Developments
  49. 7.9 SK Chemicals
  50. 7.9.1 SK Chemicals Company Information
  51. 7.9.2 SK Chemicals Business Overview
  52. 7.9.3 SK Chemicals Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 SK Chemicals Platinum Anti-tumor Drugs Product Portfolio
  54. 7.9.5 SK Chemicals Recent Developments
  55. 7.10 Qilu Pharmaceutical
  56. 7.10.1 Qilu Pharmaceutical Company Information
  57. 7.10.2 Qilu Pharmaceutical Business Overview
  58. 7.10.3 Qilu Pharmaceutical Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Qilu Pharmaceutical Platinum Anti-tumor Drugs Product Portfolio
  60. 7.10.5 Qilu Pharmaceutical Recent Developments
  61. 7.11 Dr Reddy's Laboratories
  62. 7.11.1 Dr Reddy's Laboratories Company Information
  63. 7.11.2 Dr Reddy's Laboratories Business Overview
  64. 7.11.3 Dr Reddy's Laboratories Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Dr Reddy's Laboratories Platinum Anti-tumor Drugs Product Portfolio
  66. 7.11.5 Dr Reddy's Laboratories Recent Developments
  67. 7.12 Debiopharm
  68. 7.12.1 Debiopharm Company Information
  69. 7.12.2 Debiopharm Business Overview
  70. 7.12.3 Debiopharm Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Debiopharm Platinum Anti-tumor Drugs Product Portfolio
  72. 7.12.5 Debiopharm Recent Developments
  73. 7.13 ASK Pharma
  74. 7.13.1 ASK Pharma Company Information
  75. 7.13.2 ASK Pharma Business Overview
  76. 7.13.3 ASK Pharma Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  77. 7.13.4 ASK Pharma Platinum Anti-tumor Drugs Product Portfolio
  78. 7.13.5 ASK Pharma Recent Developments
  79. 7.14 Accord Healthcare
  80. 7.14.1 Accord Healthcare Company Information
  81. 7.14.2 Accord Healthcare Business Overview
  82. 7.14.3 Accord Healthcare Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Accord Healthcare Platinum Anti-tumor Drugs Product Portfolio
  84. 7.14.5 Accord Healthcare Recent Developments
8 North America
  1. 8.1 North America Platinum Anti-tumor Drugs Revenue (2021-2032)
  2. 8.2 North America Platinum Anti-tumor Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Platinum Anti-tumor Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Platinum Anti-tumor Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Platinum Anti-tumor Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Platinum Anti-tumor Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Platinum Anti-tumor Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Platinum Anti-tumor Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Platinum Anti-tumor Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Platinum Anti-tumor Drugs Revenue by Country
  11. 8.6.1 North America Platinum Anti-tumor Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Platinum Anti-tumor Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Platinum Anti-tumor Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Platinum Anti-tumor Drugs Revenue (2021-2032)
  2. 9.2 Europe Platinum Anti-tumor Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Platinum Anti-tumor Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Platinum Anti-tumor Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Platinum Anti-tumor Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Platinum Anti-tumor Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Platinum Anti-tumor Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Platinum Anti-tumor Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Platinum Anti-tumor Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Platinum Anti-tumor Drugs Revenue by Country
  11. 9.6.1 Europe Platinum Anti-tumor Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Platinum Anti-tumor Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Platinum Anti-tumor Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Platinum Anti-tumor Drugs Revenue (2021-2032)
  2. 10.2 China Platinum Anti-tumor Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Platinum Anti-tumor Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Platinum Anti-tumor Drugs Revenue by Type (2027-2032)
  5. 10.3 China Platinum Anti-tumor Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Platinum Anti-tumor Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Platinum Anti-tumor Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Platinum Anti-tumor Drugs Revenue by Application (2027-2032)
  9. 10.5 China Platinum Anti-tumor Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Platinum Anti-tumor Drugs Revenue (2021-2032)
  2. 11.2 Asia Platinum Anti-tumor Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Platinum Anti-tumor Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Platinum Anti-tumor Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Platinum Anti-tumor Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Platinum Anti-tumor Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Platinum Anti-tumor Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Platinum Anti-tumor Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Platinum Anti-tumor Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Platinum Anti-tumor Drugs Revenue by Country
  11. 11.6.1 Asia Platinum Anti-tumor Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Platinum Anti-tumor Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Platinum Anti-tumor Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Platinum Anti-tumor Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Platinum Anti-tumor Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Platinum Anti-tumor Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Platinum Anti-tumor Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Platinum Anti-tumor Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Platinum Anti-tumor Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Platinum Anti-tumor Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Platinum Anti-tumor Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Platinum Anti-tumor Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Platinum Anti-tumor Drugs Revenue by Country
  11. 12.6.1 SAMEA Platinum Anti-tumor Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Platinum Anti-tumor Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Platinum Anti-tumor Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst